2017 American Transplant Congress
Eight Years of Low-Dose Valganciclovir; Evaluating the Incidence and Risk Factors of CMV in Kidney Transplant Recipients.
Kidney Transplant, Brigham and Women's Hostpial, Boston, MA
Introduction: Cytomegalovirus (CMV) remains one the most clinically relevant and frequent post-transplant infections. Despite the availability of effective antiviral drugs, CMV continues to be of…2017 American Transplant Congress
IdeS, an IgG Endopeptidase, Effectively Cleaves Anti-HLA Antibody (Ab), Resulting in Inhibition of Anti-HLA Ab-Mediated NK Cell Activation and Ab-Dependent Cell-Mediated Cytotoxicity (ADCC) in HLA-Sensitized Kidney Transplant Patients (HS KTx Pts).
Background: Ab-mediated rejection (ABMR) is a major obstacle in HS KTx Pts. ADCC is a mechanism responsible for ABMR. IdeS cleaves all 4 human IgG…2017 American Transplant Congress
Short Term Renal Allograft Outcomes Following Treatment of Early Subclinical Borderline Changes on Surveillance Biopsies.
University of Michigan, Ann Arbor, MI
There is no consensus on treating subclinical borderline changes on surveillance biopsy in kidney transplant (KT) recipients. We examined whether treatment with pulsed corticosteroids led…2017 American Transplant Congress
Effects of Anti-HLA Antibodies on Endothelial Expression and Serum Levels of Thrombomodulin in Kidney Recipients.
Medicine, Universite Laval, Quebec, QC, Canada
Background: Thrombomodulin (TBM) is an anticoagulant and anti-inflammatory protein expressed on endothelial cells (ECs). Mutations of TBM are seen in thrombotic microangiopathies due to aHUS.…2017 American Transplant Congress
HLA Mismatching Does Not Have an Impact on Graft or Patient Survival in Simultaneous Kidney-Pancreas Transplantation. A Single Institution Experience.
Indiana University Health, Indianapolis
Purpose: There is conflicting data on whether the level and type of HLA mismatching (MM) has an impact on pancreas, kidney, or patient survival in…2017 American Transplant Congress
High Risk Renal Transplant Recipients on Steroid Free Immunosupression Regimen. Indiana University Experience.
Renal Transplant, Indiana University School of Medicine, Indianapolis, IN
Background : Immunologic risk often influence the choice immunosuppressive regimen used in renal transplant recipient. Patient with positive flow cytometry crossmatch (FCXM) or presence of…2017 American Transplant Congress
Rabbit Anti-Human Thymocyte Immunoglobulin (rATG) for Rescue Treatment of Chronic Antibody-Mediated Rejection (cAMR) After Pediatric Kidney Transplantation.
Pediatric Nephrology, Hannover Medical School, Hannover, Germany
Background. Chronic antibody-mediated rejection (cAMR) is the leading cause of long-term graft loss after kidney transplantation. Treatment guidelines include rituximab, immunoadsorption, immunoglobulins and/or bortezomib, but…2017 American Transplant Congress
Compartmental Infiltration of Kidney Allograft with Monocyte-Macrophage Subtypes Defines the Type of Rejection.
Purpose: Rejection significantly worsens the graft function and survival. We studied monocyte-macrophage compartmental infiltration of 62 kidney transplant biopsies with diagnosis of: acute antibody mediated…2017 American Transplant Congress
Ectopic Lymphoid Structures Are Present in Type I T-Cell Mediated Kidney Transplant Rejection.
BackgroundIn renal transplantation, many allograft recipients develop donor-specific antibodies associated with an increased risk for graft rejection. Current immunosuppressive agents are principally aimed at T-cell-mediated…2017 American Transplant Congress
Belatacept for Chronic Antibody-Mediated Rejection in Kidney Transplantation.
Background: Chronic antibody mediated rejection (cAMR) is a major cause of long-term kidney transplant (KT) loss. Antibody or immune cell depletional therapies have unclear efficacy…
- « Previous Page
- 1
- …
- 114
- 115
- 116
- 117
- 118
- …
- 172
- Next Page »